COV-POPART: a vaccine cohort to evaluate immune responses to COVID-19 vaccines in specific populations

The project has been constructed with over 10 national and international learned societies and seven patient associations (France Rein - Transhépate - ARSEP - CNAO - FFD - EGMOS - TRT5 CHV*), which will also play an active role in recruiting and following up participants. The objective of the cohort is to evaluate the production of antibodies against COVID-19 in 8,650 vaccine recipients with diseases that might affect their immunity: HIV-1, diabetes (types 1 and 2), obesity, autoimmune and systemic autoinflammatory diseases (vasculitis, lupus, etc.), chronic inflammatory rheumatism, multiple sclerosis (or inflammation of the optic nerve), cancer (even without treatment for the previous 2 years), allotransplant recipients, solid organ transplant recipients (lung, liver, kidney, heart, pancreas), chronic renal failure (stages 4 and 5), and hypogammaglobulinemia (low immunoglobulin levels in the blood). In order to compare their immune responses, a control group of 1,850 vaccinated individuals without these diseases was also recruited. The cohort should also make it possible to identify potential vaccine failures and study the role of the variants in those failures. Participants will be followed for a period of two years after the last injection of the vaccine, with the help of the COVIREIVAC centers and 4 additional centers mobilized for this project. This cohort will provide essential data for vaccine policy in these vulnerable populations that are at particular risk of developing severe forms of COVID-19.